SAGE240719P10000
- 0.65
- -0.15-18.75%
Sage Therapeutics Newsroom
H.C. Wainwright Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $25
H.C. Wainwright analyst Douglas Tsao maintains $Sage Therapeutics(SAGE.US)$ with a hold rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 37.8
SAGE Therapeutics: A Balanced Hold Rating Amidst Promising Zurzuvae Launch and Clinical Pipeline Prospects
Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew rec
19 Analysts Have This To Say About Sage Therapeutics
Across the recent three months, 19 analysts have shared their insights on Sage Therapeutics (NASDAQ:SAGE), expressing a variety of opinions spanning from bullish to bearish.The following table provide
J.P. Morgan Maintains Sage Therapeutics(SAGE.US) With Buy Rating, Cuts Target Price to $23
J.P. Morgan analyst Anupam Rama maintains $Sage Therapeutics(SAGE.US)$ with a buy rating, and adjusts the target price from $28 to $23.According to TipRanks data, the analyst has a success rate of 43.
Sage Therapeutics Is Maintained at Overweight by JP Morgan
Sage Therapeutics Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $23
JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and lowers the price target from $28 to $23.
Express News | Sage Therapeutics Inc : JP Morgan Cuts Target Price to $23 From $28
The Sage Small Business Tracker Q1 2024
In collaboration with Smart Data Foundry and The Centre for Economics and Business Research (Cebr), the latest iteration of the Sage Small Business Tracker has been launched (see here for previous ver
Scotiabank Maintains Sage Therapeutics(SAGE.US) With Buy Rating, Maintains Target Price $19
Scotiabank analyst George Farmer maintains $Sage Therapeutics(SAGE.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate of 49.4% and
Oppenheimer Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $17
Oppenheimer analyst Jay Olson maintains $Sage Therapeutics(SAGE.US)$ with a hold rating, and maintains the target price at $17.According to TipRanks data, the analyst has a success rate of 44.2% and a
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $8 to $25
On Jun 12, major Wall Street analysts update their ratings for $Sage Therapeutics(SAGE.US)$, with price targets ranging from $8 to $25.Morgan Stanley analyst Vikram Purohit maintains with a hold ratin
Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Wednesday.Shares of Mama's Creations Inc (NASDAQ:MAMA) fell in today's pre-market trading following fi
HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:SAGE) with a Neutral and maintains $25 price target.
Express News | Sage Therapeutics Shares Fall 1.6%
Sage Therapeutics Is Maintained at Neutral by Baird
Sage Therapeutics Is Maintained at Neutral by Baird
Baird Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $15
Baird analyst Joel Beatty maintains $Sage Therapeutics(SAGE.US)$ with a hold rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 46.7% and a tot
Needham Maintains Sage Therapeutics(SAGE.US) With Hold Rating
Needham analyst Ami Fadia maintains $Sage Therapeutics(SAGE.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 44.4% and a total average return of 3.8% over the past
Sage Spikes After Mid-stage Win for Huntington's Disease Therapy
Express News | Sage Therapeutics Shares Reverse Course Premarket, Last Down 1%